experts said, H7N9 avian influenza DNA vaccine to complete clinical
evaluation in accordance with national legislation, officially put into
use need to wait at least six years, but experts also pointed out that
if the trend spread from person to person, or other special
circumstances arise, the vaccine can be completed a Phase I clinical
Emergency put into use after the test.
Public Health Clinical Center, Shanghai Institute of Emerging
Infectious Diseases reproduce the 7th news release, H7N9 avian influenza
DNA vaccine has completed initial development in Shanghai, many
Shanghai residents, hoping to be vaccinated as soon as possible.
In this regard, experts said sorry, H7N9 avian influenza DNA vaccine to
complete clinical evaluation in accordance with national legislation,
officially put into use need to wait at least six years, but experts
also pointed out that if the trend spread from person to person, or
other special circumstances arise, the vaccine can be completed Phase I
clinical trials after an emergency put into use. [ Ta Kung Pao reporter Xia Micro 28 (Xinhua) - Shanghai
is understood, Shanghai ongoing H7N9 avian influenza antibodies
developed in vitro testing is nearing completion, is expected to be
finalized next month, the fastest antibody screening.
Previously, Wu Fan, director of Shanghai Municipal Center for Disease
Control had explained during the breeding or selling poultry workers
suffering from H7N9 avian flu rarely the reason that "many subtypes of
avian influenza virus, the presence of cross-protection between
subtypes, that if a person infected with a constant contact subtypes,
immune machine experience, this immunity not only against infected
subtype, while the body may have the ability to resist the avian
influenza H7N9 virus. "cross-protection is a phenomenon in the same
secondary antibody was also observed in study.
H7N9 antibodies against other viruses
According 徐建青 introduced, found in the patients infected with the H7N9
virus, the immune system will produce antibodies, "we have got 53
antibody clone", it is noted that "In these antibodies, we found that
some antibodies against not only H7, also anti-H5, H3, etc. We call this
antibody called broadly neutralizing antibodies. "